TGM2 and Parkinson disease: Cys‐D, a Tgm2 inhibitor, can cross the blood–brain barrier, and is commonly used in studies of brain gliomas (Zheng et al. 2023), Huntington disease (Verny et al. 2017), and Parkinson disease (Cicchetti et al. 2019).